XML 62 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plans and Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of RSU and PSU Activity
A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December 31, 2021, 2020 and 2019 is as follows:
Nonvested RSU and PSU Activity
(In millions except weighted average grant date fair value)Shares Available for GrantSharesWeighted 
Average
Grant Date
Fair Value
Aggregate
Intrinsic Value
Balance at December 31, 20183.2 2.7 $69.19 
Additional shares authorized2.2 — 
Granted(0.7)0.7 144.37 
Vested— (1.4)69.45 
Forfeited0.2 (0.2)83.45 
Balance at December 31, 20194.9 1.8 96.63 $392.0 
Granted(0.5)0.5 300.36 
Vested— (1.0)92.07 
Forfeited0.1 (0.1)137.44 
Balance at December 31, 20204.5 1.2 183.51 430.6 
Granted(0.4)0.4 351.32 
Vested— (0.7)137.90 
Forfeited0.1 (0.1)279.12 
Balance at December 31, 20214.2 0.8 $307.86 $411.3 
Schedule of Share-Based Compensation Expenses The following table summarizes the share-based compensation expense included in our consolidated statements of operations for the periods shown.
Twelve Months Ended
December 31,
(In millions)202120202019
Cost of sales$8.5 $14.6 $9.0 
Research and development41.0 37.8 33.5 
Selling, general and administrative63.9 67.0 60.2 
Total share-based compensation expense$113.4 $119.4 $102.7 
Schedule of Valuation Assumptions for Employee Stock Purchase Plan We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.
 Twelve Months Ended
December 31,
202120202019
Risk free interest rate
0.06% - 0.07%
0.13% - 0.95%
1.72% - 2.55%
Dividend yield— %— %— %
Expected volatility of Dexcom common stock
36% - 45%
51% - 63%
40% - 51%
Expected life (in years)0.50.51